COMMUNIQUÉS West-GlobeNewswire

Mithra Pharmaceuticals: MITHRA ANNOUNCES 2017 HALF YEAR RESULTS

21/09/2017 - 07:30

Regulated information MIThRA ANNOUNCES 2017 HALF YEAR RESULTS Liège, Belgium, 21 September 2017 - Mithra (Euronext Brussels: MITRA), a company specialized in women's health, today announces its financial results for the [...]

Biocartis Group NV: Disclosure of a transparency notification

21/09/2017 - 07:00

PRESS RELEASE: REGULATED INFORMATION 21 September 2017, 07:00 CEST Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Mechelen, [...]

La fondation Dangote et GBCHealth unissent leurs forces pour construire une coalition autour de la santé

21/09/2017 - 04:20

NEW YORK, le 21 septembre 2017 (GLOBE NEWSWIRE) - La fondation Dangote ( www.Dangote.com ) et GBCHealth ont uni leurs forces pour donner naissance à un nouveau modèle de partenariat, l'African Business Coalition on [...]

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure

21/09/2017 - 00:23

DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug [...]

ProtectMyPeople - A New Group Life Insurance Comparison Site - Launches for UK Small and Medium Business Owners

20/09/2017 - 18:48

Price comparison experts, the idol.com have launched the UK's first ever price comparison site for "Death in Service" insurance ProtectMyPeople aims to make group employee benefits more accessible for business owners. [...]

GENFIT : Risque de confusion entre elafibranor, candidat médicament de type PPAR alpha/delta (Phase 3), et lanifibranor, composé de type PPAR a/d/gamma (Phase 2)

20/09/2017 - 18:24

GENFIT : Risque de confusion entre elafibranor, candidat médicament de type PPAR alpha/delta (Phase 3), et lanifibranor, composé de type PPAR a/d/gamma (Phase 2) Alerte initiale sur un risque potentiel d'erreur médicale [...]

GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor

20/09/2017 - 18:24

GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor Initial alert on potential medication error raised by Prescrire , an independent [...]

Summit Therapeutics plc : Holding(s) in Company

20/09/2017 - 17:15

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Summit Therapeutics [...]

Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory Board

20/09/2017 - 15:03

Synthego strengthens position with appointment while accelerating worldwide commercial growth REDWOOD CITY, CA--(Marketwired - Sep 20, 2017) - Synthego , a leading provider of genome engineering solutions, announces the [...]

Optalysys, Ltd. Raises $4 Million Seed Round to Break Bottlenecks in Genomic Research and Big Data Analysis

20/09/2017 - 15:00

Light-Speed Optical Processing Startup to Democratize Access to High-Powered Computing and Drive Advances in Research and Development GLASSHOUGHTON, WEST YORKSHIRE, United Kingdom and RENO, Nev., Sept. 20, 2017 (GLOBE [...]

Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27

20/09/2017 - 14:00

ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced [...]

XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

20/09/2017 - 14:00

AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its [...]

Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

20/09/2017 - 12:58

Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy - Investigational RNAi Therapeutic Patisiran Meets Primary [...]

Sanofi et Alnylam rapportent les premiers résultats positifs de l'étude de phase 3 APOLLO consacrée au patisiran dans le traitement de la polyneuropathie amyloïde familiale à la transthyrétine

20/09/2017 - 12:58

Sanofi et Alnylam rapportent les premiers résultats positifs de l'étude de phase 3 APOLLO consacrée au patisiran dans le traitement de la polyneuropathie amyloïde familiale à la transthyrétine - L'agent thérapeutique [...]

Gyroscope Therapeutics appoints Dr Soraya Bekkali as Chief Executive Officer

20/09/2017 - 11:24

Gyroscope Therapeutics appoints Dr Soraya Bekkali as Chief Executive Officer London (UK) - 20 September, 2017: Gyroscope Therapeutics, an ophthalmology company developing genetically defined therapies for retinal [...]

Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHD

20/09/2017 - 08:00

Shire and Shionogi Announce Positive Topline Results for INTUNIV® (guanfacine hydrochloride prolonged release) Evaluated in Phase 3 Clinical Trial in Adults with ADHD Topline results revealed the study met its primary [...]

Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

20/09/2017 - 07:15

Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1] As the first and only therapy for advanced SM in the EU, Rydapt offers a new [...]

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

20/09/2017 - 07:00

Top-line data from the study expected in second half of 2018 - September 20, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep [...]

Bone Therapeutics SA : announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

20/09/2017 - 07:00

Regulated information Bone Therapeutics announces all patients meet primary endpoint in ALLOB ® Phase I/IIA delayed-union study interim analysis DSMB recommends concluding the study early based on positive efficacy data [...]